
A new study reveals that Candida auris and related species may develop cross-resistance to both fluconazole and manogepix, a promising antifungal in trials. Mutations in transcriptional regulators like TAC1B and PDR1 appear to drive resistance via overexpression of drug efflux transporters such as Cdr1, raising major concerns for future treatment options.
Like
Save
Share